• Treatment of hyperprolactinemia (idiopathic or pituitary in origin).

Contraindicated in:

• Hypersensitivity to cabergoline or ergot alkaloids
• Uncontrolled hypertension
• History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
• History of cardiac valvular disease
• Lactation: Has been associated with hypertension, stroke, and seizures. Not to be used for suppression of physiologic lactation.

Use Cautiously in:

• Hepatic impairment
• Patients who have received medications associated with valvular disorders
• OB: Use only if clearly needed
• Pedi: Safety not established.

CNS: dizziness, headache, depression, drowsiness, fatigue, impulse control disorders (gambling, sexual), nervousness, vertigo, weakness.

Resp: PULMONARY FIBROSIS, pleural effusion.

EENT: abnormal vision.

CV: PERICARDIAL FIBROSIS, VALVULAR DISORDERS, postural hypotension, hot flashes.

GI: RETROPERITONEAL FIBROSIS, constipation, nausea, abdominal pain, dyspepsia, vomiting.

GU: dysmenorrhea.

Endo: breast pain.

Neuro: paresthesia.

Drug-Drug:

• ↑risk of hypotension with antihypertensives.
• May ↑ the effects of SSRIs and other serotonin agonists (induces serotonin syndrome).
• Effectiveness may be ↓ by phenothiazines, butyrophenones (haloperidol), thioxanthenes, or metoclopramide (avoid concurrent use).

(Generic available)

• Tablets: 0.5 mg;

• PO (Adults): 0.25 mg twice weekly; may be ↑ at 4-wk intervals up to 1 mg twice weekly.

Dostinex

• Inhibits secretion of prolactin by acting as a dopamine agonist.

• Decreased secretion of prolactin in hyperprolactinemia.

Therapeutic Classification: antihyperprolactinemic

Pharmacologic Classification: dopamine agonists

Absorption: Well absorbed but undergoes extensive first-pass hepatic metabolism.

Distribution: Widely distributed; concentrates in pituitary.

Metabolism/Excretion: Extensively metabolized by the liver; <4% excreted unchanged in urine.

Protein Binding: 40–42%.

Half-life: 63–69 hr.

(effect on serum prolactin levels)

• Instruct patient to take medication as directed. Take missed doses as soon as possible within 1 or 2 days. If not remembered until time of next dose, double dose. If nausea occurs, discuss with health care professional.
• May cause drowsiness and dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
• Advise patient to change positions slowly to minimize orthostatic hypotension.
• Caution patient to avoid concurrent use of alcohol during therapy.
• Instruct patients taking cabergoline for pituitary tumors to inform health care professional immediately if signs of tumor enlargement occur (blurred vision, sudden headache, severe nausea, and vomiting).
• Advise patient to notify health care professional if signs of valvular disorders (shortness of breath, swelling in extremities) occurs.
• Advise patient to notify health care professional if new or increased gambling, sexual, or other impulse control disorders occur.
• Advise women to consult with health care professional regarding a nonhormonal method of birth control. Women should contact health care professional promptly if pregnancy is planned or suspected.
• Emphasize the importance of regular follow-up exams to determine effectiveness and monitor side effects.

ka-BER-goe-leen

NDC Code^*

• 0093- Teva Pharmaceuticals USA, Inc.
  • 0093-5420- Cabergoline
    • 0093-5420-88- 1 BOTTLE in 1 CARTON (0093-5420-88) > 8 TABLET in 1 BOTTLE

• 49884- Par Pharmaceutical, Inc.
  • 49884-673- Cabergoline
    • 49884-673-14- 8 TABLET in 1 BOTTLE (49884-673-14)

• 50090- A-S Medication Solutions
  • 50090-3157- Cabergoline
    • 50090-3157-0- 1 BOTTLE in 1 CARTON (50090-3157-0) > 8 TABLET in 1 BOTTLE

• 50090- A-S Medication Solutions
  • 50090-3951- Cabergoline
    • 50090-3951-0- 8 TABLET in 1 BOTTLE (50090-3951-0)

• 50742- Ingenus Pharmaceuticals, LLC
  • 50742-118- Cabergoline
    • 50742-118-08- 8 TABLET in 1 BOTTLE (50742-118-08)

• 59762- Greenstone LLC
  • 59762-1005- Cabergoline
    • 59762-1005-1- 8 TABLET in 1 BOTTLE (59762-1005-1)

• 68071- NuCare Pharmaceuticals,Inc.
  • 68071-4596- Cabergoline
    • 68071-4596-8- 8 TABLET in 1 BOTTLE (68071-4596-8)

• 70518- REMEDYREPACK INC.
  • 70518-2379- Cabergoline
    • 70518-2379-0- 8 POUCH in 1 BOX, UNIT-DOSE (70518-2379-0) > 1 TABLET in 1 POUCH (70518-2379-1)